Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
KRW 114400.0
(-4.75%)
KRW 114400.0
(-4.75%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 16 Billion KRW | -76.41% |
| 2022 | 67.82 Billion KRW | 160.25% |
| 2021 | 26.06 Billion KRW | 30.3% |
| 2020 | 20 Billion KRW | 168.37% |
| 2019 | 7.45 Billion KRW | 3.83% |
| 2018 | 7.17 Billion KRW | 139.24% |
| 2017 | 3 Billion KRW | 0.0% |
| 2016 | - KRW | 0.0% |
| 2015 | - KRW | 0.0% |
| 2014 | - KRW | -100.0% |
| 2013 | 1.37 Billion KRW | -78.66% |
| 2012 | 6.44 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 16 Billion KRW | 0.0% |
| 2024 Q1 | 16 Billion KRW | 0.0% |
| 2023 Q2 | 20 Billion KRW | 0.0% |
| 2023 Q1 | 20 Billion KRW | -70.51% |
| 2023 FY | 16 Billion KRW | -76.41% |
| 2023 Q4 | 16 Billion KRW | 279.19% |
| 2023 Q3 | 4.21 Billion KRW | -78.9% |
| 2022 Q4 | 67.82 Billion KRW | 0.67% |
| 2022 FY | 67.82 Billion KRW | 160.25% |
| 2022 Q3 | 67.37 Billion KRW | 43.58% |
| 2022 Q2 | 46.92 Billion KRW | 0.95% |
| 2022 Q1 | 46.48 Billion KRW | 78.36% |
| 2021 Q3 | 25.64 Billion KRW | -43.3% |
| 2021 Q4 | 26.06 Billion KRW | 1.64% |
| 2021 FY | 26.06 Billion KRW | 30.3% |
| 2021 Q2 | 45.22 Billion KRW | 126.1% |
| 2021 Q1 | 20 Billion KRW | -17.18% |
| 2020 Q1 | 9.51 Billion KRW | -0.61% |
| 2020 Q3 | 12.21 Billion KRW | 23.13% |
| 2020 Q4 | 24.14 Billion KRW | 97.69% |
| 2020 Q2 | 9.92 Billion KRW | 4.27% |
| 2020 FY | 20 Billion KRW | 168.37% |
| 2019 Q3 | 7.68 Billion KRW | 0.29% |
| 2019 Q2 | 7.66 Billion KRW | 1.69% |
| 2019 Q1 | 7.53 Billion KRW | 4.96% |
| 2019 FY | 7.45 Billion KRW | 3.83% |
| 2019 Q4 | 9.57 Billion KRW | 24.61% |
| 2018 Q2 | - KRW | -100.0% |
| 2018 Q1 | 3 Billion KRW | 0.0% |
| 2018 Q4 | 7.17 Billion KRW | 0.0% |
| 2018 FY | 7.17 Billion KRW | 139.24% |
| 2018 Q3 | - KRW | 0.0% |
| 2017 FY | 3 Billion KRW | 0.0% |
| 2017 Q2 | - KRW | 0.0% |
| 2017 Q3 | - KRW | 0.0% |
| 2017 Q4 | 3 Billion KRW | 0.0% |
| 2017 Q1 | - KRW | 0.0% |
| 2016 Q3 | - KRW | 0.0% |
| 2016 FY | - KRW | 0.0% |
| 2016 Q1 | - KRW | 0.0% |
| 2016 Q4 | - KRW | 0.0% |
| 2016 Q2 | - KRW | 0.0% |
| 2015 Q1 | - KRW | 0.0% |
| 2015 Q4 | - KRW | 0.0% |
| 2015 Q3 | - KRW | 0.0% |
| 2015 Q2 | - KRW | 0.0% |
| 2015 FY | - KRW | 0.0% |
| 2014 Q1 | 1.37 Billion KRW | 0.0% |
| 2014 FY | - KRW | -100.0% |
| 2014 Q3 | - KRW | 0.0% |
| 2014 Q2 | - KRW | -100.0% |
| 2014 Q4 | - KRW | 0.0% |
| 2013 Q1 | 6.44 Billion KRW | 0.0% |
| 2013 Q2 | 13.73 Billion KRW | 113.29% |
| 2013 FY | 1.37 Billion KRW | -78.66% |
| 2013 Q3 | 13.82 Billion KRW | 0.61% |
| 2013 Q4 | 1.37 Billion KRW | -90.06% |
| 2012 FY | 6.44 Billion KRW | 0.0% |
| 2012 Q4 | 6.44 Billion KRW | 0.0% |
| 2012 Q3 | - KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Hyundai Bioscience Co., Ltd. | 32.43 Million KRW | -49233.991% |
| ST Pharm Co.,Ltd. | 159.68 Billion KRW | 89.981% |
| ABL Bio Inc. | 43 Billion KRW | 62.791% |
| Cellid, Co., Ltd. | 6.48 Billion KRW | -146.638% |